

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



SINO BIOPHARMACEUTICAL LIMITED

中國生物製藥有限公司

(Incorporated in the Cayman Islands with limited liability)

Website: www.sinobiopharm.com

(Stock code: 1177)

VOLUNTARY ANNOUNCEMENT

THREE RESEARCH RESULTS OF “TQC3721 (PDE3/4 INHIBITOR)” AND “TQC2731 (TSLP MONOCLONAL ANTIBODY)” WILL BE PRESENTED AT ERS 2024

The board of directors (the “**Board**”) of Sino Biopharmaceutical Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) announces that three research results of two innovative drugs developed by the Group, “TQC3721 (PDE3/4 inhibitor)” and “TQC2731 (TSLP monoclonal antibody)”, will be presented at the 2024 annual meeting of European Respiratory Society (ERS 2024) to be held on 7th to 11th of September.

TQC3721 (PDE3/4 inhibitor)

TQC3721 is an inhaled PDE3/4 inhibitor intended for the maintenance therapy of chronic obstructive pulmonary disease (COPD) and is the second fastest developing drug in the world amongst innovative drugs with the same target. Currently, TQC3721 has completed phase I and phase IIa clinical trials, and its research data will be published at ERS 2024 in the form of poster, one of which is the Late Breaking Abstract.

Phase I: Safety, Tolerability and Pharmacokinetics of the Phosphodiesterase 3/4 (PDE3/4) Inhibitor TQC3721 Suspension for Inhalation in Healthy Adult Subjects

Phase IIa: Late Breaking Abstract – A Dose-Ranging Study of the Inhaled Dual PDE3/4 Inhibitor TQC3721 in COPD Patients

Corresponding Author: Professor Li Weimin, West China Hospital, Sichuan University

First Author: Professor Luo Zhu, West China Hospital, Sichuan University

TQC2731 (TSLP monoclonal antibody)

TQC2731 is a TSLP monoclonal antibody, currently undergoing phase II clinical trial in patients with asthma and chronic sinusitis with nasal polyps, and its development progress is among the fastest in the world. The phase I study data will be published in the form of a poster at ERS 2024.

Phase I: Safety, tolerability, pharmacokinetics, and immunogenicity of a human monoclonal antibody TQC2731 targeting thymic stromal lymphopoietin (TSLP) in healthy Chinese adults

Corresponding Author: Tian Xin, The First Affiliated Hospital of Zhengzhou University

First Author: Tian Xin, The First Affiliated Hospital of Zhengzhou University

ERS is the world's largest professional conference in the field of respiratory diseases, and the inclusion of our three research results at ERS 2024 demonstrates the breakthroughs achieved by the Group in the respiratory field. In the future, the Group will continue its efforts in the respiratory field and explore new innovative drugs and treatment programmes.

By order of the Board
Sino Biopharmaceutical Limited
Tse, Theresa Y Y
Chairwoman

Hong Kong, 26 August 2024

As at the date of this announcement, the Board of the Company comprises six executive directors, namely Ms. Tse, Theresa Y Y, Mr. Tse Ping, Ms. Cheng Cheung Ling, Mr. Tse, Eric S Y, Mr. Tse Hsin and Mr. Tian Zhoushan, and five independent non-executive directors, namely Mr. Lu Zhengfei, Mr. Li Dakui, Ms. Lu Hong, Mr. Zhang Lu Fu and Dr. Li Kwok Tung Donald.